Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
17 Literatur zu Teil IV (Kapitel 15–17)
Alikhan R, Cohen AT, Combe S et al. (2003) Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 14: 341–346
Alikhan R, Cohen AT, Combe S et al. (2004) Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 164: 963–968
Anderson FA Jr, Wheeler HB, Goldberg RJ et al. (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151: 933–938
Belch JJ, Lowe GDO, Ward AG, Forbes CD, Prentice CRM (1981) Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 26: 115–117
Clarke-Pearson DL, Synan IS, Colemen RE, Hinshaw W, Creasman WT (1984) The natural history of postoperative venous thromboemboli in gynaecologic oncology: a prospective study of 382 patients. Am J Obstet Gynecol 148: 1051–1054
Cohen AT et al. (2003) J Thromb Haemost 1[Suppl 1]: P2046
Emerson PA, Marks P (1977) Preventing thromboembolism after myocardial infarction: effect of low-dose heparin or smoking. BMJ 1: 18–20
Fraisse F, Holzapfel L, Coulaud J-M et al. (2000) Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. Am J Respir Crit Care Med 161: 1109–1114
Geerts WH, Heit JA, Clagett GP et al. (2001) Prevention of venous thromboembolism. Chest 119: 132S–175S
Handley AJ (1972) Low-dose heparin after myocardial infarction. Lancet 2: 623–624
Kierkegaard A, Norgren L, Olsson C-G, Castenfors J, Persson G, Persson S (1987) Incidence of deep vein thrombosis in bedridden non-surgical patients. Acta Med Scand 222: 409–414
Kleber F-X, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, for THE-PRINCE Study Group (2003) A randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145: 614–621
Kniffin WD Jr, Baron JA, Barrett J et al. (1994) The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154: 861–866
Laffen M, Tuddenham E (1998) Science, medicine, and the future: Assessing thrombotic risk. Br Med J 317: 520–523
Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 17: 874–879
Levine MN, Gent M, Hirsh J et al. (1988) The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318: 404–407
Lutz L, Haas S et al. (2002) Venöse Thromboembolie in der Inneren Medizin: Risikoeinschätzung und medikamentöse Prophylaxe. Med Welt 53: 231–234
Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma. An evidence-based review. Cancer 89: 640–646
Nicolaides AN, Breddin HK, Fareed J et al. (2001) Prevention of venous thromboembolism. International Consensus Statement Guidelines compiled in accordance with the scientific evidence. Int Angiol 20: 137
Otten HMMB, Prins MH, Smorenburg SM, Hutten BA (2000) Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: cancer as a risk factor. Haemostasis 30[Suppl 2]: 72–76
Samama M-M (2000) An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients. Arch Intern Med 160: 3415–3420
Samama MM, Cohen AT, Darmon J-Y et al. (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341: 793–800
Saphner T, Tormey DC, Gray R (1991) Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9: 286–294
Sutherland DE, Weitz IC, Liebman HA (2003) Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 72: 43–52
Warlow C, Beattie AG, Terry G, Ogston D, Kenmure ACF, Douglas AS (1973) A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet 2: 934–936
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Haas, S. (2005). Modelle zur Risikoabschätzung. In: Haas, S. (eds) Prävention von Thrombosen und Embolien in der Inneren Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27118-X_17
Download citation
DOI: https://doi.org/10.1007/3-540-27118-X_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-22563-8
Online ISBN: 978-3-540-27118-5
eBook Packages: Medicine (German Language)